H.R. 2940 118th Congress
PASTEUR Act
- Health
- Sponsor: Rep. Ferguson, A. Drew, IV [R-GA-3]
- Congress.gov ↗
Latest action, Dec 17, 2024: Referred to the Subcommittee on Health.
How the Senate voted
The Senate hasn't taken a roll call on this bill in the Congresses covered.
62 cosponsors
Sponsored by Rep. Ferguson, A. Drew, IV [R-GA-3] (Republican). Cosponsors by party, House members included:
- Democrats
- Republicans
- Independents
Cosponsors
31 D · 31 R
- Democrat
- Republican
- Independent
Referred to: House: Budget Committee; House: Energy and Commerce Committee; House: Oversight and Government Reform Committee; House: Ways and Means Committee
Who lobbied on it
Clients whose quarterly lobbying reports named it, each quarter.
The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.
7 reports
7 reports
INFECTIOUS DISEASES SOCIETY OF AMERICA
ARENTFOX SCHIFF LLP
7 reports
7 reports
7 reports
MERCK & CO. INC.
AVENUE SOLUTIONS
7 reports
SEPSIS ALLIANCE
LINCHPIN STRATEGIES, LLC
7 reports
7 reports
6 reports
6 reports
BIOTECHNOLOGY INNOVATION ORGANIZATION (BIO)
TIBER CREEK GROUP
6 reports
HART HEALTH STRATEGIES
TIM YEHL, LLC
5 reports
All 25 of 28 clients
| Client | Lobbying firm | Reports | Reports totaling | From | To | Senate |
|---|---|---|---|---|---|---|
| INFECTIOUS DISEASES SOCIETY OF AMERICA | 8 | $1.6M | Q1 2023 | Q3 2024 | yes | |
| AMERICAN COLLEGE OF EMERGENCY PHYSICIANS | 7 | $3.2M | Q4 2023 | Q3 2024 | yes | |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | 7 | $13.3M | Q4 2023 | Q3 2024 | yes | |
| CYSTIC FIBROSIS FOUNDATION | 7 | $1.4M | Q4 2023 | Q3 2024 | yes | |
| HEALTHCARE INSTITUTE OF NEW JERSEY | 7 | $397K | Q4 2023 | Q3 2024 | yes | |
| INFECTIOUS DISEASES SOCIETY OF AMERICA | ARENTFOX SCHIFF LLP | 7 | $0 | Q4 2023 | Q3 2024 | yes |
| JOHNSON & JOHNSON SERVICES INC | 7 | $12.1M | Q4 2023 | Q3 2024 | yes | |
| MERCK & CO INC | 7 | $16.2M | Q4 2023 | Q3 2024 | yes | |
| MERCK & CO. INC. | AVENUE SOLUTIONS | 7 | $0 | Q4 2023 | Q3 2024 | yes |
| SEPSIS ALLIANCE | LINCHPIN STRATEGIES, LLC | 7 | $160K | Q4 2023 | Q3 2024 | yes |
| SHIONOGI INC. | 7 | $810K | Q4 2023 | Q3 2024 | yes | |
| AMERICAN KIDNEY FUND | 6 | $1.1M | Q4 2023 | Q3 2024 | yes | |
| AMERICAN SOCIETY FOR MICROBIOLOGY | 6 | $300K | Q4 2023 | Q3 2024 | yes | |
| BIOTECHNOLOGY INNOVATION ORGANIZATION (BIO) | TIBER CREEK GROUP | 6 | $360K | Q4 2023 | Q3 2024 | yes |
| HART HEALTH STRATEGIES | TIM YEHL, LLC | 5 | $200K | Q4 2023 | Q3 2024 | yes |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | AVOQ, LLC | 3 | $0 | Q4 2023 | Q3 2023 | yes |
| GSK (FKA GLAXOSMITHKLINE INC.) | 3 | $3.4M | Q4 2023 | Q3 2023 | yes | |
| HEALTHCARE LEADERSHIP COUNCIL | 3 | $340K | Q2 2023 | Q3 2024 | yes | |
| VIZIENT INC | 3 | $1.4M | Q4 2023 | Q3 2023 | yes | |
| BIOMERIEUX | 2 | $390K | Q4 2024 | Q3 2024 | yes | |
| NATIONAL MULTIPLE SCLEROSIS SOCIETY | 2 | $150K | Q2 2023 | Q3 2023 | yes | |
| NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) | 2 | $90K | Q3 2023 | Q1 2024 | yes | |
| SHIONOGI INC. | BURRELL INTERNATIONAL GROUP LLC | 2 | $0 | Q4 2023 | Q3 2023 | yes |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | AKIN GUMP STRAUSS HAUER & FELD | 1 | $0 | Q2 2023 | Q2 2023 | yes |
| COUNTY OF KERN | CARPI & CLAY, INC | 1 | $20K | Q3 2023 | Q3 2023 | yes |